文献速递慢性肾脏病肾血管病与高血压血液净化与透析

Volenrelaxin(LY3540378)增加肾血浆流量:一项随机1期试验

Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trial.
PubMed 文献 · Nephrol Dial Transplant · 2024-01-01

该1期随机双盲安慰剂对照研究在健康受试者中评估Volenrelaxin单次和多次递增给药的安全性、耐受性、药代动力学和药效学。

要点

  • Volenrelaxin半衰期延长,支持每周一次皮下给药。
  • mGFR不变,滤过分数和肾小动脉阻力降低,血压下降、脉率增加。

核心结论

  • Volenrelaxin耐受性良好、安全,适合每周皮下给药,重复给药可持续改善肾脏灌注,支持在慢性肾脏病和慢性心力衰竭中进一步临床开发。

研究设计与样本

  • 1期、四部分、随机、双盲、安慰剂对照的单次和多次递增剂量研究,在健康受试者中进行。
  • 单次给药组n=56,接受静脉或皮下剂量递增的Volenrelaxin或安慰剂。
  • 多次给药组n=77,每周皮下注射Volenrelaxin或安慰剂一次,共5周。
  • ERPF和mGFR分别通过对氨基马尿酸和碘海醇清除率测定。

主要发现

  • mGFR不变,滤过分数和入/出球小动脉阻力降低。
  • 随Volenrelaxin暴露增加,收缩压和舒张压下降、脉率增加,模型推导的安慰剂校正最大变化(90%置信区间)分别为-6.16(-8.04,-4.28)mmHg、-6.10(-7.61,-4.58)mmHg和+4.39(+3.38,+5.39)bpm。
  • 不良事件轻微,Volenrelaxin与安慰剂组间体位性低血压无差异。

临床怎么用

  • Volenrelaxin可考虑用于改善肾脏灌注,但需进一步在慢性肾脏病和慢性心力衰竭患者中验证。
  • 每周一次皮下给药方案具有可行性。

局限性

  • 研究在健康受试者中进行,尚未在目标患者人群中验证。
  • 样本量有限,长期安全性和疗效未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Volenrelaxin is a half-life-extended recombinant human relaxin protein developed for improving kidney perfusion and cardiorenal function. This study assessed the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of volenrelaxin following single- and multiple-ascending doses (SAD and MAD) administration. METHODS: In this Phase 1, four-part, randomized, double-blinded, placebo-controlled SAD and MAD study in healthy participants, SAD participants (n = 56) received an intravenous or subcutaneous dose of volenrelaxin or placebo in a dose-ascending manner. MAD participants (n = 77) received volenrelaxin or placebo subcutaneously once weekly for 5 weeks. Effective renal plasma flow (ERPF) and measured glomerular filtration rate (mGFR) were determined by para-aminohippurate and iohexol clearance, respectively. RESULTS: Volenrelaxin demonstrated an extended half-life and increased acute and chronic placebo-adjusted ERPF change from baseline by 50% and 44%, respectively (P < .0001). mGFR was unchanged, while filtration fraction and afferent/efferent renal arteriolar resistances were reduced. Systolic and diastolic blood pressures decreased, and pulse rate increased with increasing volenrelaxin exposures, demonstrating maximal model-derived placebo-adjusted changes (90% confidence interval) of -6.16 (-8.04, -4.28) mmHg, -6.10 (-7.61, -4.58) mmHg and +4.39 (+3.38, +5.39) bpm, respectively. Adverse events were mild, with no difference in orthostatic hypotension between volenrelaxin and placebo. CONCLUSION: Volenrelaxin was well-tolerated, safe and suitable for weekly subcutaneous dosing. Volenrelaxin showed a sustained improvement in kidney perfusion upon repeated dosing, supporting further clinical development in chronic kidney disease and chronic heart failure. CLINICAL TRIAL REGISTRATION: NCT04768855.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Tham LS, Heerspink HJL, Wang X, et al. Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trial. Nephrol Dial Transplant. 2024. PMID: 38782726. doi:10.1093/ndt/gfae112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。